Skip to content

Sutro Biopharma STRO Short- term Investments

Short- term Investments at other companies

Gilead Sciences logo
Gilead SciencesGILD
Regenxbio logo
RegenxbioRGNX
Schrodinger logo
SchrodingerSDGR
Roivant Sciences logo
Roivant SciencesROIV
Nuvation Bio logo
Nuvation BioNUVB
Tango Therapeutics logo
Tango TherapeuticsTNGX

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's short- term investments?
Sutro Biopharma (STRO) reported short- term investments of $128.88M in Q1 2026.
How has Sutro Biopharma's short- term investments changed year-over-year?
Sutro Biopharma's short- term investments decreased by 9.7% year-over-year, from $142.74M to $128.88M.
What is the long-term trend for Sutro Biopharma's short- term investments?
Over 5 years (2020 to 2025), Sutro Biopharma's short- term investments has grown at a -7.1% compound annual growth rate (CAGR), from $120.34M to $83.3M.